Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Working Group Prof. Dr. Dr. Melanie Börries

Contact:

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Straße 17
D-79104 Freiburg
Phone: +49-761-203 9626                 
m.boerries@dkfz.de
http://www.mol-med.uni-freiburg.de/mom/boerries/fo

Research Focus:

Systems Biology of Cellular Microenvironment

The group focuses on the elucidation of tumor-stroma interactions in cancer and cancer progression on the genome, transcriptome and proteome level. Using multi-omics approaches together with statistical analysis and in silico modeling and simulation the group tries to unravel the onset of tumor-stroma interactions and their modulation during tumor progression. For this, they uniquely combine in their own lab medical expertise with dry- and wet-lab experiments to analyze patient material in conjunction with in vitro experiments and modeling. Their area of research is not restricted to a particular tumor entity. Instead, they try to uncover generic regulatory schemes between healthy and diseased cells and how these are modulated in the particular tumor entity.

CRC 850: Cancer Invasion and Metastasis
Project Z1 – Clinical validation and bioinformatics (Busch, Börries)

DKTK Reseach Topics:

  • Detection of mutated, free circulating tumor DNA and noncoding RNA in plasma of patients with resectable, stage I-IIIA non-small cell lung cancer (Co-Work with Prof. Nikolas von Bubnoff, Prof. Silke Laßmann, PD Dr. Irina Nazarenko)
  • Delineating the genetic heterogeneity in the Tumor-Stroma Interaction in Pancreatic Adenocarcinoma (Co-Work with Dr. Peter Bronsert)
  • Identification of genetic drivers in childhood MDS using WES and RNA-
  • Sequencing (Co-Work with Dr. Marcel Wlodarski)
  • Mutation Analysis and functional characterization of juvenile myelomonocytic leukemia (Co-Work with Prof. Dr. Christian Flotho and Prof. Charlotte Niemeyer)
  • Morphologisch kontrollierte, quantitative RNA und DNA Analysen von gematchten Kryo-und FFPE Geweben: epitheliale Tumoren und assoziiertes Normalepithel, inklusive Primärtumore und Metastasen. (Co-Work with Prof. Dr. Silke Laßmann)
  • Mutational Analysis form Ewing Sarcomas (Co-Work with Prof. Dr. Udo Kodny, Uniklinik RWTH Aachen)
  • Targeting the Kinome to induce differentiation in human breast cancer stem cells ((Co-Work with Dr. Jochen Maurer, DKTK Freiburg)
  • Multivariate modeling tumor progression of colorectal cancer (Co-Work with Prof. Dr. Roland Rad, Klinikum rechts der Isar der Technischen Universität München

Working Group Members DKTK:

http://www.mol-med.uni-freiburg.de/mom/boerries/mit

Selected Publications:

Sulaimanov N, Klose M, Busch H, Boerries M. Understanding the mTOR signaling pathway via mathematical modeling. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. Februar 2017;e1379.

Strotbek M, Schmid S, Sànchez-Gonzàlez I, Boerries M, Busch H, Olayioye MA. miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer: PHLPP2 and INPP4B targeting by miR-181. International Journal of Cancer [Internet]. Februar 2017 [zitiert 7. März 2017]; Verfügbar unter: doi.wiley.com/10.1002/ijc.30661

Nkuipou-Kenfack E, Schanstra JP, Bajwa S, Pejchinovski M, Vinel C, Dray C, Valet P, Bascands J-L, Vlahou A, Koeck T, Borries M, Busch H, Bechtel-Walz W, Huber TB, Rudolph KL, Pich A, Mischak H, Zürbig P. The use of urinary proteomics in the assessment of suitability of mouse models for ageing. Kim J, Herausgeber. PLOS ONE. 15. Februar 2017;12(2):e0166875.

Krebs AM, Mitschke J, Losada ML, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology [Internet]. 17. April 2017 [zitiert 19. April 2017]; Verfügbar unter: www.nature.com/doifinder/10.1038/ncb3513

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget [Internet]. 17. April 2017 [zitiert 7. Juni 2017]; Verfügbar unter: www.oncotarget.com/abstract/17160

Adlung L, Kar S, Wagner M, She B, Chakraborty S, Bao J, Lattermann S, Boerries M, Busch H, Wuchter P, Ho AD, Timmer J, Schilling M, Höfer T, Klingmüller U. Protein abundance of AKT and ERK pathway components governs cell type‐specific regulation of proliferation. Molecular Systems Biology. Januar 2017;13(1):904.

Strietz J, Stepputtis SS, Preca B-T, Vannier C, Kim MM, Castro DJ, Au Q, Boerries M, Busch H, Aza-Blanc P, Heynen-Genel S, Bronsert P, Kuster B, Kuster B, Stickeler E, Brabletz T, Oshima RG, Maurer J. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer. Oncotarget [Internet]. 4. November 2016 [zitiert 11. November 2016]; Verfügbar unter: www.oncotarget.com/abstract/13086

Offermann B, Knauer S, Singh A, Fernández-Cachón ML, Klose M, Kowar S, Busch H, Boerries M. Boolean Modeling Reveals the Necessity of Transcriptional Regulation for Bistability in PC12 Cell Differentiation. Frontiers in Genetics [Internet]. 14. April 2016 [zitiert 13. April 2017];7. Verfügbar unter: journal.frontiersin.org/Article/10.3389/fgene.2016.00044/abstract

Lerchenmüller C, Heißenberg J, Damilano F, Bezzeridis VJ, Krämer I, Bochaton-Piallat M-L, Hirschberg K, Busch M, Katus HA, Peppel K, Rosenzweig A, Busch H, Boerries M, Most P. S100A6 Regulates Endothelial Cell Cycle Progression by Attenuating Antiproliferative Signal Transducers and Activators of Transcription 1 Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology. 7. Juli 2016;ATVBAHA.115.306415.

Fluhr S, Boerries M, Busch H, Symeonidi A, Witte T, Lipka DB, Mücke O, Nöllke P, Krombholz CF, Niemeyer CM, Plass C, Flotho C. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia. Clinical Epigenetics [Internet]. Dezember 2016 [zitiert 11. Mai 2016];8(1). Verfügbar unter: clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-016-0216-3

Boerries M, Herr R, Brummer T, Busch H. Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. Genomics Data. Juni 2015;4:158–61.

-- Logo: © dkfz.de

Prof. Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 49
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
++49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de

Dr. Anna Dost
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 77121
a.dost@dkfz-heidelberg.de